Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients
A recent analysis of data from the phase 3 Checkmate-214 [...]
A recent analysis of data from the phase 3 Checkmate-214 [...]
The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr [...]
Tivozanib is expected to be included as a first-line treatment [...]
Results from the JAVELIN Renal 101 phase 3 study to [...]
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
Yesterday it was announced that the combination of ipilimumab and [...]
We are delighted that the Scottish Medicines Consortium (SMC), which reviews [...]
The National Institute for Health and Care Excellence (NICE) have issued an [...]
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from [...]